Tag: PFS
-
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs
Understanding the Debate: Dose Escalation for Somatostatin Analogs in GEP-NETs Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a heterogeneous landscape, with treatment aims centered on controlling tumor growth, managing symptoms, and preserving quality of life. Somatostatin analogs (SSAs), such as octreotide and lanreotide, have long been foundational therapies due to their ability to curb hormonal symptoms and…
-
Lu-177 PNT2002 Combined with SBRT Delays Prostate Cancer Progression
Overview New data presented at the American Society for Radiation Oncology (ASTRO) meeting suggest that adding the radiopharmaceutical Lu-177 PNT2002 to stereotactic body radiation therapy (SBRT) can significantly delay disease progression in men with oligometastatic, or limited, prostate cancer. The LUNAR trial compared SBRT alone to a two-cycle course of Lu-177 PNT2002 followed by SBRT,…